Abstract | OBJECTIVE: DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: English-language randomized controlled trials and review articles were evaluated. DATA SYNTHESIS: CONCLUSIONS:
PDE-5 inhibitors consistently reduce LUTS associated with BPH. These medications may offer advantages over conventional therapies such as rapid onset of action, fewer adverse effects, and enhanced sexual function. Quality of life improvements have also been realized in men with BPH who receive PDE-5 inhibitors.
|
Authors | Mindi S Miller |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 47
Issue 2
Pg. 278-83
(Feb 2013)
ISSN: 1542-6270 [Electronic] United States |
PMID | 23386068
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Carbolines
- Imidazoles
- Phosphodiesterase 5 Inhibitors
- Piperazines
- Purines
- Sulfones
- Triazines
- Vasodilator Agents
- Vardenafil Dihydrochloride
- Tadalafil
- Sildenafil Citrate
|
Topics |
- Adrenergic alpha-Antagonists
(adverse effects, therapeutic use)
- Carbolines
(adverse effects, therapeutic use)
- Drug Resistance
- Drug Therapy, Combination
(adverse effects)
- Erectile Dysfunction
(etiology, prevention & control)
- Humans
- Imidazoles
(adverse effects, therapeutic use)
- Lower Urinary Tract Symptoms
(etiology, prevention & control)
- Male
- Phosphodiesterase 5 Inhibitors
(adverse effects, therapeutic use)
- Piperazines
(adverse effects, therapeutic use)
- Prostate
(drug effects)
- Prostatic Hyperplasia
(drug therapy, physiopathology)
- Purines
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Sildenafil Citrate
- Sulfones
(adverse effects, therapeutic use)
- Tadalafil
- Triazines
(adverse effects, therapeutic use)
- Vardenafil Dihydrochloride
- Vasodilator Agents
(adverse effects, therapeutic use)
|